Myeloma

“Only you have the power to make your life better,” says a myeloma survivor on living for the moment after a cancer diagnosis.

A new genetic test that identifies patients with multiple myeloma who have high-risk genetics may help oncologists find alternative treatment options before the disease progresses.

“I just want people to know that when they say you have cancer, they are not saying you have a death sentence. You can still live and you can live well.”

Patients with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy experienced a durable clinical benefit after receiving melflufen (Oncopeptides) in combination with dexamethasone.

The Food and Drug Administration approved the targeted therapy Sarclisa for the treatment of patients with multiple myeloma. Here’s what you need to know.

Terry White, who has lived with multiple myeloma for more than a decade, offers reassurance to other patients.

In this episode of the “CURE Talks Cancer” podcast, we spoke with the co-chair of the MMRF’s Laugh for Life event, as well as this year’s “Spirit of Hope” award recipient.

The Food and Drug Administration approved Sarclisa, as adding the targeted drug to combination therapy delays the progression of multiple myeloma in previously treated patients.

Patient Rod Gilmore shares his experience with multiple myeloma and the importance of creating a strategy to manage the disease.

The Food and Drug Administration granted a priority review to belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma.

A multiple myeloma expert helps newly diagnosed patients understand the standard of care for their disease.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Cesar Rodriguez about precision medicine, and his recent trek to Patagonia with Moving Mountains for Multiple Myeloma.

Patients with multiple myeloma have a lot to look forward to in the treatment space thanks to precision medicine, but one treatment option alone will not cure the disease.

At the 2019 CURE® Educated Patient® Summit on Multiple Myeloma patient advocate and 10-year survivor Terry White had the chance to share advice on handling a cancer diagnosis.

Naturally, newly diagnosed patients with multiple myeloma have a lot of questions for their physicians. Dr. Joshua Richter had the time to discuss some of them.

At CURE’s Educated Patient Summit on Multiple Myeloma Dr. Shebli Atrash had the chance to further discuss with CURE what questions he addresses most when patients with multiple myeloma undergo diagnostic testing.

At CURE’s Educated Patient Summit on Multiple Myeloma, Dr. Barry Paul discussed the role of minimal residual disease measurement and how it may be used in the future to determine treatment options for patients with myeloma.

Dr. Cesar Rodriguez offers a message of hope and self-determination for patients with multiple myeloma.